Safety Profile
Below is a selection of the observed side effects; please refer to the SmPc or the package leaflet for the complete list.
Myelosuppression
Patients who develop anaemia may need blood transfusions. Dose adjustment or...Twitter Linkedin Facebook Pinterest Google plusDose recommendation
Reimbursement
Mechanism of Action
Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 a nd for myelofibrosis (MF). 6
JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...Twitter Linkedin Facebook Pinterest Google plusIndications
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report...
Twitter Linkedin Facebook Pinterest Google plusEfficacy
Wet AMD Visual acuity and outcomes with Beovu in clinical trialsAt Week 48, brolucizumab demonstrated non-inferiority to aflibercept in mean BCVA change from baseline in HAWK (p<0.001). • Visual acuity gains achieved at Week 48...
Twitter Linkedin Facebook Pinterest Google plusSafety profile
▼Beovu ® (brolucizumab) is indicated in adults for the treatment of neovascular (wet) AMD and visual impairment due to DME 1 Safety profile with Beovu in clinical trials Beovu exhibited an overall well-tolerated safety...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action
Reimbursement / eHealth
Beovu® (brolucizumab) is reimbursed in Grand-Duché de Luxembourg, not in Belgium.
Twitter Linkedin Facebook Pinterest Google plus